EGFR and ovarian carcinoma: In line with this, the dual EDNRA/B inhibitor macitentan blocked metastatic progression of ovarian cancer cells [258,259,260,261], and zibotentan, a specific EDNRA inhibitor showed synergistic effects on apoptosis and inhibition of ovarian cancer cell invasion, when used in combination with EGFR inhibitors [275,276].